Pfizer

The short interest moves in biotech and emerging pharmaceutical companies were mixed in the latter two weeks of April. The number of shares sold short in Dendreon (NASDAQ: DNDN), Gilead Sciences (NASDAQ: GILD), Illumina (NASDAQ: ILMN), Onyx Pharmaceuticals (NASDAQ: ONXX) and VIVUS (NASDAQ: VVUS)...

First-quarter results from General Motors (NYSE: GM) will be one of the highlights on the earnings front this week. Analysts anticipate that the carmaker will say Thursday its revenue slipped about three percent from a year ago to $36.60 billion, but that earnings fell from $0.93 per share a year...

Eli Lilly (NYSE: LLY), which last week announced a deal to buy two imaging agents from Siemens (NYSE: SI) that could help aid the fight against Alzheimer's, is scheduled to report its first-quarter 2013 results Wednesday, April 24, before the markets open. Investors will be watching for the latest...

Question: What can you print with a 3D printer? Answer: Almost anything. Still skeptical? Consider this. Four years ago, restaurant manager Eric Moger, lost almost the entire left side of his face due to emergency cancer surgery. Now, according to The Province, thanks to cutting-edge, three-...

The short interest in biotech and emerging pharmaceutical companies was mixed again in the first two weeks of March. The number of shares sold short in Arena Pharmaceuticals (NASDAQ: ARNA), Dendreon (NASDAQ: DNDN), Illumina (NASDAQ: ILMN) and VIVUS (NASDAQ: VVUS) grew somewhat between the...

“This is where money goes to die,” has described one sector over the past decade but this year, things are different. That industry is health care and for the first time since 1988, it leads the S&P with a 12 percent gain—the most among the 10 main groups. Specifically, health insurers,...

A recent report in MarketWatch claimed that if Apple (NASDAQ: AAPL) doesn’t change its ideas towards dividends or buybacks, or finds something else to do with its cash, by the end of 2013 it could reach $170 billion. According to Moody’s, “Unless Apple changes its philosophy towards liquidity/...

On Wednesday, Spectrum Pharmaceuticals (NASDAQ: SPPI) dropped 37 percent after releasing its Q1 and full year revenue guidance. The company said it expects sales of its colorectal cancer drug, Fusilev, to total $80 to $90 million in 2013 compared to $204 million in 2012. Seem like a huge drop...

A recent Australian study points toward possible good news in the search for answers regarding Alzheimer’s disease. The Border Mail reports that Australians will be among the first to test new drugs hoped to ward off Alzheimer’s after researchers discovered that the illness takes decades to...

The short interest in biotech and emerging pharmaceutical companies was mixed again in the first two weeks of January. The number of shares sold short in Arena Pharmaceuticals (NASDAQ: ARNA), Dendreon (NASDAQ: DNDN), Gilead Sciences (NASDAQ: GILD), Onyx Pharmaceuticals (NASDAQ: ONXX) and Vertex...